©The Author(s) 2026.
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 112944
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.112944
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.112944
Figure 3 Kaplan-Meier estimates of progression-free survival and overall survival according to low ascites burden and high ascites burden.
A: Progression-free survival; B: Overall survival. LAB: Low ascites burden; HAB: High ascites burden.
- Citation: Matsumoto T, Sugimoto S, Omori R, Makiyama C, Nakasya A, Nagai H, Yasui H, Higashi R, Sasamoto A, Satake H. Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites. World J Gastrointest Oncol 2026; 18(1): 112944
- URL: https://www.wjgnet.com/1948-5204/full/v18/i1/112944.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i1.112944